AzTrials
AzTrials

Endodontically Retard TeethNCT07256561

Antimicrobial and Anti-inflammatory Effects of Simvastatin as an Intracanal Medication

A study testing Simvastatin as an intracanal medication in people with Endodontically Retard Teeth and Periapical Radiolucency, run by Hadeer Maher Mostafa Mohamed at 1 site in Egypt.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Successful endodontic treatment and a predictable outcome can only be achieved by effective root canal debridement, irrigation, and elimination of microorganisms . The outcome of endodontic treatment performed in controlled clinical environment has demonstrated success rate around 90%. Read more about this study

Who is it for?
Ages 20 to 40 years
What is being tested?
Simvastatin as an intracanal medication
Could I receive a placebo?
No, everyone receives an active treatment
How many people
54 participants
Where
1 siteEgypt
Study dates
10 Aug 2025to 10 Aug 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 40 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients had anon contributory medical history.
  • Patients of age categories between 20 to 40 years old, with no physical disability or psychological problems.
  • Single rooted teeth with type I root canal anatomy.
  • Symptomatic cases of failed endodontic treatment with radiographic evidence of periapical bone loss, and the lesion size ranging from 2mm up to 8mm.

Who cannot join

  • Patients with known sensitivity to the pharmaceutical used in this trial
  • Patients with former endodontic mishaps (as ledges, transportations, perforations or separated instruments)
  • Non restorable teeth
  • Presence of an associated sinus tract.
  • Advanced periodontal involvement
  • Teeth representing root fracture.
  • Pregnant women

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Hadeer Maher Mostafa Mohamed, MSc contact

+201024990619

hadeer.maher@den.suezuni.edu.eg

Mervat Ibrahim Fawzy, Professor contact

+201005376344

mervat_3105@yahoo.com

Egypt1 site, 1 recruiting
  • Faculty of Dental Medicine for Girls, Al-Azhar University

    Cairo

    Asmaa Abd El-Hady Mohamed Fahmy, Lecturer, +201225825960, asmaaabdelhady.26@azhar.edu.eg

    Recruiting

Other trials in Egypt

About this study

Official title: Antimicrobial and Anti-inflammatory Effects of Simvastatin as an Intracanal Medication in Endodontically Retreated Teeth With Periapical Radiolucency, Randomized Controlled Clinical Trial

Successful endodontic treatment and a predictable outcome can only be achieved by effective root canal debridement, irrigation, and elimination of microorganisms .

The outcome of endodontic treatment performed in controlled clinical environment has demonstrated success rate around 90%.

Read more

In certain cases, endodontic treatment may fail, one of the most common reasons is inability to eliminate microorganisms from the root canal. When non-surgical root canal therapy fails, the treatment options include orthograde re-treatment, periradicular surgery, or extraction.

Simvastatin (SIM) is a drug used primarily to treat hyperlipidemia and protect against cardiovascular diseases. It has been shown to possess pleiotropic effects such as antimicrobial, anti-inflammatory, immunomodulatory, antioxidant, and bone-forming properties .

The side chain of this material has a single methyl group. It inhibits hydroxymethyl glutarylcoenzyme reductase that prevents endogenous cholesterol synthesis

Read the detailed description

It has been reported that the inflamed/infected periodontal/endodontic content influence cytokines release . These inflammatory mediators, such as interleukin (IL)-1β, tumor necrosis factor α (TNF-α), and prostaglandin E2 (PGE2), have been detected in periapical tissues and root canal exudates .

Proinflammatory cytokines are able to stimulate, either directly or indirectly, the release of matrix metalloproteinases (MMPs) in the periapical/periodontal region, maintaining a persistent inflammatory process. MMPs are deeply involved in the pathogenesis of pulp, periodontal, and periapical tissue destruction.

As a Gram-positive, facultative anaerobe, Enterococcus Faecalis (E. Faecalis) can survive root canal treatment . It can form biofilms and survive prolonged periods of nutritional deprivation. It can also resist acidic and basic conditions and is hard to eradicate .

  1. Faecalis is responsible for 20-70% of endodontic failures and secondary endodontic infections . Due to biofilm development and the organism's physicochemical characteristics, which enable it to alter the prevailing environmental and nutritional conditions, it can even thrive in constrained environments .

Accumulated evidence indicates that the tissue destruction in endodontic and periodontal infections is due to host-derived cytokines induced by lipopolysaccharides (LPS/endotoxins), acting as the major components of the outer leaflet of the outer membrane of gram-negative bacteria.

Calcium hydroxide (Ca (OH)2) has been widely used as an intracanal medicament for retreatment of such failed cases, due to its high pH, its ability to stimulate mineralization, its antibacterial properties, and its tissue-dissolving capability .

Hydroxyl ions create free radicals that destroy components of bacterial cell membranes. These free radicals react with bacterial DNA inhibiting DNA replication and cell activity, and cause mutations. Also, the alkaline pH of calcium hydroxide alters enzyme activity, disrupting cellular metabolism and structural proteins .

Simvastatin enhances alkaline phosphatase activity and mineralization and increases the expression of bone sialoprotein, osteocalcin, and type I collagen, and it is shown to have an anti-inflammatory effect by decreasing the production of interleukin-6 and interleukin-8. SIM is reported to stimulate vascular endothelial growth factor (VEGF) release in a dose dependent manner, and the authors of a previous study suggested that statins may promote osteoblast differentiation and bone nodule formation by stimulating VEGF expression in bone tissue.

Simvastatin is also a renowned safe and affordable medication. It is a novel medicinal substance that is still undergoing dental research . Various animal and clinical studies showed that SIM assists in bone regeneration as well as the anti-inflammatory effect when delivered or applied locally.

Periapical radiography is an essential resource in endodontic diagnosis because it offers important evidence on the progression, regression, and persistence of apical periodontitis (AP) . It is known that periapical radiolucency might not be visible radiographically, although they exist clinically. Conventional radiographs used for the management of endodontic problems yield limited information because of the two-dimensional (2D) nature of the images produced, geometric distortion and anatomical noise.

Being tested
Simvastatin as an intracanal medication

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Simvastatin as an intracanal medicationProcedure or surgery

    Also called calcium hydroxide intracanal medication

    to evaluate the antimicrobial and anti-inflammatory effects of Simvastatin as an intracanal medication in endodontic retreatment of single rooted teeth with periapical radiolucency.

Study groups in NCT07256561
Study groupRoleWhat they receive
Simvastatin GroupActive comparatorAbout 27 Patients will take Simvastatin 10mg tablets which will be crushed into fine particles and dissolved to prepare an intracanal medication with specific concentration according to the antimicrobial sensitivity study.
Receives: Procedure: Simvastatin as an intracanal medication
Calcium hydroxideActive comparatorAbout 27 Patients will be injected by Calcium hydroxide intracanal medication in endodontic retreatment of single rooted teeth with periapical radiolucency.
Receives: Procedure: Simvastatin as an intracanal medication

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Simvastatin antimicrobial effect

    Following the treatment, patients will be asked to evaluate The antimicrobial effect of Simvastatin intracanal medication

    Measured: 6 Months

Secondary outcomes (1)
  1. Simvastatin anti-inflammatory effect

    Following the treatment, patients will be asked to evaluate The anti-inflammatory effect of Simvastatin intracanal medication and periapical radiolucency healing.

    Measured: 6 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Dec 2025
  2. Study start10 Aug 2025
  3. Primary completion1 Aug 2026 (estimated)
  4. Study completion10 Aug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
54 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07256561
Sponsor's protocol ID
Effects of Simvastatin
Status last verified
Aug 2025
First submitted
20 Nov 2025
Last updated
1 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Simvastatin as an intracanal medication in people with Endodontically Retard Teeth and Periapical Radiolucency, run by Hadeer Maher Mostafa Mohamed at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 1 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Hadeer Maher Mostafa Mohamed, MSc (+201024990619, hadeer.maher@den.suezuni.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Simvastatin antimicrobial effect (time frame: 6 Months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in